• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British journal of ophthalmology >Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma.
【24h】

Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma.

机译：使用韦替泊芬进行光动力疗法治疗外接脉络膜血管瘤。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: To investigate the safety and efficacy of photodynamic therapy with verteporfin in patients with choroidal haemangioma. METHODS: A non-randomised, prospective clinical investigation of 19 patients with symptomatic circumscribed choroidal haemangioma was performed. Unsuccessful pretreatment (external beam irradiation, laser photocoagulation) was performed in four patients. Patients were included when (1) subretinal exudation involving the fovea, (2) a decrease in visual function, and (3) additional symptoms (for example, metamorphopsia) were present. Photodynamic therapy (PDT) was performed with verteporfin at a concentration of 6 mg/m(2) body surface area and a light dose of 100 J/cm(2) at 692 nm. RESULTS: The mean follow up time was 10.6 months (2-24 months). The mean number of treatment sessions was 2.15 (range 1-5). Visual acuity improved by at least one line in 73.3%, by at least two lines in 42.1%, was stable in 21.1%, and decreased by one line in 5.2% of the patients. Exudation was completely resolved in 94.8% of the cases. Regression of tumour height was documented in all 19 tumours. Patients receiving any pretreatment before PDT, a visual acuity of 0.1 and less, a history of more than 30 months, and no significant response after the first PDT session, did not show any significant improvement. Cox regression analysis revealed that the number of PDT treatment sessions was inversely associated with the improvement in visual acuity of at least two lines. No recurrences and no local or systemic side effects were observed during the follow up time. CONCLUSION: PDT using verteporfin is a safe and effective therapy for the treatment of symptomatic choroidal haemangioma even in tumours located beneath the fovea.
机译：目的：探讨韦替泊芬光动力疗法治疗脉络膜血管瘤的安全性和有效性。方法：对19例有症状性外接脉络膜血管瘤的患者进行了非随机前瞻性临床研究。四个患者进行了不成功的预处理（外部束照射，激光光凝）。 （1）视网膜中央凹下累及中央凹，（2）视觉功能下降，以及（3）出现其他症状（例如，变态）时，将患者包括在内。用Verteporfin进行光动力疗法（PDT），浓度为6 mg / m（2）体表面积，在692 nm处的光剂量为100 J / cm（2）。结果：平均随访时间为10.6个月（2-24个月）。平均疗程数为2.15（范围1-5）。视力至少提高了73.3％，至少增加了22.1％，稳定了21.1％，而5.2％的患者下降了1％。 94.8％的病例渗出得到完全解决。在所有19种肿瘤中均记录了肿瘤高度的消退。在PDT之前接受任何预处理，视敏度小于等于0.1，病史超过30个月且在第一次PDT疗程后无明显反应的患者没有显示任何明显改善。 Cox回归分析显示，PDT治疗疗程的数量与至少两行视力的提高呈负相关。在随访期间未观察到复发，也未观察到局部或全身性副作用。结论：使用维替泊芬的PDT是治疗症状性脉络膜血管瘤的一种安全有效的疗法，即使在位于中央凹下方的肿瘤中也是如此。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号